| 123 Discussion of toxicity and biomarkers in a phase i trial of gefitinib (IRESSATM) in combination with radiation or chemo-radiation for patients with locally advanced head … D Raben, C Chen, M Kane, J Song, G Eckhardt, A Meyers, K McCoy, ... Radiotherapy and Oncology, S39, 2006 | | 2006 |
| 30 Combinations of Molecular-Targeted Therapies HX Chen, JE Dancey Molecular Targeting in Oncology, 693, 0 | | |
| 408 A phase II study of erlotinib in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (PHL-002e/NCIC CTG IND. 157) E Winquist, D Soulieres, E Chen, M Tsao, M Klein, G Pond, J Dancey, ... EJC Supplements 8 (2), 122, 2004 | 4 | 2004 |
| 430 Phase I and pharmacokinetic study of UCN-01 (U) in combination with irinotecan (I) in patients with solid tumors A Jimeno, MA Rudeck, WT Purcell, Y Zabelina, K Elza-Brown, T Rogers, ... EJC Supplements 8 (2), 129, 2004 | 1 | 2004 |
| 550 POSTER Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors I Duran, S Hotte, E Chen, H Hirte, M MacLean, S Turner, G Pond, J Wright, ... European Journal of Cancer Supplements 4 (12), 167, 2006 | 7 | 2006 |
| 649 Update on the toxicity and response of a phase I trial of concurrent, daily gefitinib and radiation or chemo-radiation for patients with locally advanced squamous cell … D Raben, M Kane, C Chen, J Song, L Brualdi, A Raben, K Hu, ... EJC Supplements 8 (2), 196, 2004 | 2 | 2004 |
| 790 Gender specific differences baseline of quality of life (QL) assessments in lung cancer patients: results from four National Cancer Institute of Canada Clinical Trials … J Dancey, B Zee, D Osoba, M Whitehead, M Palmer, F Shepherd, J Pater Lung Cancer, 203-204, 1997 | | 1997 |
| A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas T Bekaii-Saab, J Markowitz, N Prescott, W Sadee, N Heerema, L Wei, ... Clinical Cancer Research 15 (18), 5895-5901, 2009 | 136 | 2009 |
| A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer SS Sridhar, SJ Hotte, JL Chin, GR Hudes, R Gregg, J Trachtenberg, ... American journal of clinical oncology 33 (6), 609-613, 2010 | 73 | 2010 |
| A multicenter Phase II study of lapatinib in recurrent or metastatic adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT) M Agulnik, EE Cohen, RB Cohen, EX Chen, SJ Hotte, E Winquist, ... ANNALS OF ONCOLOGY 17, 179-179, 2006 | 4 | 2006 |
| A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS) E Warner, R Goel, J Chang, W Chow, S Verma, J Dancey, E Franssen, ... British journal of cancer 77 (12), 2376-2380, 1998 | 43 | 1998 |
| A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment SE Taube, GM Clark, JE Dancey, LM McShane, CC Sigman, SI Gutman Journal of the national cancer institute 101 (21), 1453-1463, 2009 | 131 | 2009 |
| A pharmacokinetic and pharmacodynamic Phase 1 study of UCN-01 and irinotecan in resistant solid tumors. PM Fracasso, MA Rudek, MJ Ellis, SA Goodner, J Dancey, HL McLeod CLINICAL CANCER RESEARCH 11 (24), 8985S-8985S, 2005 | | 2005 |
| A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies PM Fracasso, KJ Williams, RC Chen, J Picus, CX Ma, MJ Ellis, BR Tan, ... Cancer chemotherapy and pharmacology 67, 1225-1237, 2011 | 72 | 2011 |
| A Phase 2 study of perifosine in advanced or metastatic breast cancer NB Leighl, S Dent, M Clemons, TA Vandenberg, R Tozer, DG Warr, ... Breast cancer research and treatment 108, 87-92, 2008 | 116 | 2008 |
| A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC) EE Vokes, EEW Cohen, AM Mauer, TG Karrison, SJ Wong, ... Journal of Clinical Oncology 23 (16_suppl), 5504-5504, 2005 | 111 | 2005 |
| A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors ET Lam, CL O'Bryant, M Basche, DL Gustafson, N Serkova, A Baron, ... Molecular cancer therapeutics 7 (12), 3685-3694, 2008 | 11 | 2008 |
| A Phase I Study of Pegylated Liposomal Doxorubicin Hydrochloride (Caelyx™) in Combination with Cyclophosphamide and Vincristine as Second-Line Treatment of Patients with Small … NB Leighl, RL Burkes, JE Dancey, PG Lopez, BP Higgins, PLD Walde, ... Clinical lung cancer 5 (2), 107-112, 2003 | 15 | 2003 |
| A phase I trial and pharmacokinetic study of gefitinib in pediatric patients with refractory solid tumors: a Children's Oncology Group Study NC Daw, WL Furman, CF Stewart, LC Iacono, M Krailo, M Bernstein, ... Journal of Clinical Oncology 22 (14_suppl), 8522-8522, 2004 | 2 | 2004 |
| A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer S Trudel, J Trachtenberg, A Toi, J Sweet, Z Hua Li, M Jewett, J Tshilias, ... Cancer Gene Therapy 10 (10), 755-763, 2003 | 94 | 2003 |
